Evidence map›Paper›PMID 42733887›Full record

ArticleInternational journal of nanomedicine2026

Nanoengineered GATA3

Peiwen Zhang, Yahong Xu, Yimeng Zhang, Jing Yang, Shuyun Liu, Yujia Yuan, Younan Chen, Chunhong Li, Yanrong Lu, Hui Wang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Peiwen Zhang *Department of General Surgery and NHC Key Laboratory of Transplant Engineering and Immunology, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.ORCID 0000-0003-4637-4094
Yahong Xu *Department of General Surgery and NHC Key Laboratory of Transplant Engineering and Immunology, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.
Yimeng ZhangDepartment of General Surgery and NHC Key Laboratory of Transplant Engineering and Immunology, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.ORCID 0009-0002-2754-8757
Jing YangLaboratory of Omics Technology and Bioinformatics, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.ORCID 0000-0001-7678-8875
Shuyun LiuDepartment of General Surgery and NHC Key Laboratory of Transplant Engineering and Immunology, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.
Yujia YuanDepartment of General Surgery and NHC Key Laboratory of Transplant Engineering and Immunology, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.
Younan ChenDepartment of General Surgery and NHC Key Laboratory of Transplant Engineering and Immunology, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.
Chunhong LiDepartment of Pharmaceutical Sciences, School of Pharmacy, Southwest Medical University, Luzhou, 646000, People's Republic of China.
Yanrong LuDepartment of General Surgery and NHC Key Laboratory of Transplant Engineering and Immunology, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.
Hui WangDepartment of Periodontics, State Key Laboratory of Oral Diseases, National Center for Stomatology, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, 610041, People's Republic of China.
Jingping LiuDepartment of General Surgery and NHC Key Laboratory of Transplant Engineering and Immunology, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Severe skeletal muscle injury is a serious disease worldwide, but current clinical treatments are unsatisfactory because of the limited ability of these treatments to repair muscle; thus, novel therapies that can efficiently promote muscle regeneration are desirable. Methods: Nanoengineered GATA3 Results: Our data revealed that dysregulation of GATA3⁺ macrophage subsets and the accumulation of harmful dead cells compromised the MuSC niche after severe skeletal muscle injury. In vitro, GATA3 Conclusion: This study highlights that the tailored design of engineered immune cell therapy is a promising strategy for promoting MuSC niche restoration and regeneration following acute chemically induced skeletal muscle injury.

Indexed as

MacrophagesMuscle, SkeletalNanoparticlesRegenerationStem Cell NicheAnimalsEfferocytosisLactic AcidMaleMiceMice, Inbred C57BLPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerLactic AcidPolyglycolic AcidPolylactic Acid-Polyglycolic Acid Copolymerdrug deliveryefferocytosismacrophageregenerative medicineskeletal muscle injury

Identifiers

PMID42733887
PMCPMC13571681

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.